Helix BioPharma Corp
HBP
Company Profile
Business description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.
Contact
40 Temperance Street
Suite 2700, Bay Adelaide Centre - North Tower
TorontoONM5H0B4
CANT: +1 604 684-2181
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 July 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,637.50 | 22.80 | -0.26% |
| CAC 40 | 7,717.06 | 34.83 | -0.45% |
| DAX 40 | 23,930.31 | 67.17 | -0.28% |
| Dow JONES (US) | 42,270.07 | 54.34 | 0.13% |
| FTSE 100 | 8,777.90 | 5.52 | 0.06% |
| HKSE | 23,157.97 | 131.80 | -0.57% |
| NASDAQ | 19,113.77 | 62.10 | -0.32% |
| Nikkei 225 | 37,470.67 | 494.43 | -1.30% |
| NZX 50 Index | 12,418.89 | 137.58 | 1.12% |
| S&P 500 | 5,911.69 | 0.48 | -0.01% |
| S&P/ASX 200 | 8,414.10 | 20.60 | -0.24% |
| SSE Composite Index | 3,347.49 | 15.96 | -0.47% |